A clinical trial explores the safety and efficacy of low-intensity shockwave therapy (LiSWT) as a treatment option for people suffering from erectile dysfunction.
Erectile dysfunction (ED) is a common problem affecting many men worldwide. It is a condition that makes it difficult for men to maintain an erection during sexual activity. The causes of ED can be physical or psychological, and it can be a source of frustration and embarrassment for many men.
In recent years, low-intensity shockwave therapy (LiSWT) has emerged as a potential treatment for vasculogenic ED. LiSWT involves using low-intensity shockwaves to stimulate the growth of new blood vessels in the penis, improving blood flow and helping to achieve and maintain an erection. However, well-designed clinical trials justifying its use in vasculogenic ED were lacking.
To correct this, a clinical trial was conducted that examined the early outcomes of a short course of LiSWT for patients suffering from ED.
Clinical TrialThe trial included 51 men aged 18 years or older with erectile dysfunction symptoms present for at least 1 month. The men were divided into two groups: the treatment group, which received LiSWT, and the control group, which received a sham treatment. The treatment group received a total of 4 LiSWT sessions over the course of 4 weeks, while the control group did not.
The patients were re-assessed at 1, 3, and 6 months post-therapy. The International Index of Erectile Function-5 and Erection Hardness Score (EHS) questionnaires were used for the evaluation of ED.
ResultsThe results of the clinical trial showed that LiSWT was a safe and effective treatment for ED. After 4 weeks of treatment, the men in the treatment group showed significant improvement in their erectile function compared to the control group. The treatment group had higher scores on the International Index of Erectile Function, which is a standard measure of erectile function. The LiSWT group also demonstrated better EHS scores at 1, 3, and 6 months post-therapy.
The study also found that LiSWT was a well-tolerated treatment with no serious adverse effects reported in the patients undergoing LiSWT.
ConclusionOverall, this clinical trial provides promising evidence that LiSWT could be a safe and effective treatment option for men with vasculogenic ED. The treatment is non-invasive, well-tolerated, and has the potential to improve erectile function and quality of life.
If you or someone you know is struggling with ED, it's important to talk to a healthcare provider to determine the best treatment option. While LiSWT shows promise, it may not be suitable for everyone, and there are other treatment options available that may be more appropriate depending on individual circumstances.
Journal of Andrologia, Oct-22